Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 103
Filtrar
Mais filtros










Filtros aplicados

Base de dados
Intervalo de ano de publicação
1.
Int. j. morphol ; 37(2): 515-521, June 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1002253

RESUMO

SUMMARY: Reproductive dysfunction is a complication for many diseases and toxins. Its early diagnosis and treatment are immensely important. Here the morphological histoarchitecture changes in early testicular and cauda toxicity before and after treatment with angiotensin receptor blockers were evaluated. Low-grade testicular damage was induced using thioacetamide (TAA, 50 mg/kg/day) intraperitoneally for two weeks in rats. The rats were randomly divided into four groups (n = 8) treated daily orally for three weeks as follows: Normal control (distilled water), TAA (positive control), TAA+candesartan (0.2 mg/kg) and TAA+losartan (7.5 mg/kg). Serum testosterone and testicular malondialdehyde and glutathione were measured. The changes in histoarchitecture of testis and cauda epididymis were evaluated by hematoxylin and eosin for general structure, Masson's trichrome for collagen, periodic acid Schiff for basement membrane, and caspase-3 and proliferating cell nuclear antigen (PCNA) for immunohistochemical analysis. The TAA-rats showed decreases of serum testosterone and testicular glutathione, increases in testicular malondialdehyde, degenerative changes and apoptosis in germ cells, thickening of tubular basal lamina and increases in expression of caspase 3, and decreases in expression of PCNA. The ARBs (candesartan and losartan) significantly reversed these changes with non-significant differences in-between. Treatment with ARBs (candesartan and losartan) significantly reversed TAA-induced low-grade testicular and cauda toxicity in rats. This could be potentially useful for early treatment of male patients with occupational toxicant-induced reproductive dysfunction especially if they are using ARBs for other comorbidities.


RESUMEN: La disfunción reproductiva es una complicación por muchas enfermedades y toxinas. Su diagnóstico y tratamiento tempranos son inmensamente importantes. Aquí se evaluaron los cambios morfológicos en la histoarquitectura en la toxicidad precoz testicular y cauda antes y después del tratamiento con bloqueadores de receptores de angiotensina. Se indujo daño testicular de bajo grado usando tioacetamida (TAA, 50 mg / kg / día) por vía intraperitoneal durante dos semanas en ratas. Las ratas se dividieron aleatoriamente en cuatro grupos (n = 8) tratados diariamente por vía oral durante tres semanas de la siguiente manera: control normal (agua destilada), TAA (control positivo), TAA + candesartan (0,2 mg / kg) y TAA + losartán (7,5 mg / kg). Se midieron la testosterona sérica, el malondialdehído testicular y el glutatión. Los cambios en la histoarquitectura de los testículos y la epidermis de la cauda se evaluaron mediante Hematoxilina y Eosina para determinar la estructura general, con tricrómicro de Masson para el colágeno, ácido periódico de Schiff para la membrana basal y la caspasa-3 y el antígeno nuclear de células proliferantes (PCNA) para análisis inmunohistoquímico. Las ratas TAA mostraron disminución de la testosterona sérica y glutatión testicular, aumentos en el malondialdehído testicular, cambios degenerativos y apoptosis en células germinales, engrosamiento de la lámina basal tubular y aumentos en la expresión de la caspasa 3, y disminución en la expresión de PCNA. Los ARB (candesartán y losartán) revirtieron significativamente estos cambios con diferencias no significativas en el medio. El tratamiento con BRA (candesartán y losartán) revirtió significativamente la toxicidad testicular y cauda inducida por TAA en ratas. Esto podría ser potencialmente útil para el tratamiento temprano de pacientes con disfunción reproductiva inducida por tóxicos ocupacionales, especialmente si están usando BRA para otras comorbilidades.


Assuntos
Animais , Masculino , Ratos , Testículo/efeitos dos fármacos , Tioacetamida/toxicidade , Benzimidazóis/farmacologia , Losartan/farmacologia , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Testículo/patologia , Testosterona/análise , Tetrazóis/farmacologia , Imuno-Histoquímica , Ratos Sprague-Dawley , Antígeno Nuclear de Célula em Proliferação/metabolismo , Caspase 3/metabolismo , Glutationa/análise , Malondialdeído/análise
2.
Braz. J. Pharm. Sci. (Online) ; 55: e17776, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1039048

RESUMO

Albendazole and fenbendazole are imidazole derivatives that exhibit broad spectrum activity against parasites, but the low solubility of these drugs considerably reduces their effectiveness. Complexation of albendazole and fenbendazole with cyclodextrins (ß-cyclodextrin and hydroxypropyl-ß-cyclodextrin) in both water and an aqueous solution of polyvinylpyrrolidone (PVP-k30) was studied to determine if it could increase the solubility and dissolution rate of the drugs. In an aqueous solution, ß-cyclodextrin increased the solubility of albendazole from 0.4188 to ~93.47 µg mL-1 (223×), and of fenbendazole from 0.1054 to 45.56 µg mL-1 (432×); hydroxypropyl-ß-cyclodextrin, on the other hand, increased solubility to ~443.06 µg mL-1 (1058×) for albendazole and ~159.36 µg mL-1 (1512×) for fenbendazole. The combination of hydroxypropyl-ß-cyclodextrin and polyvinylpyrrolidone enabled a solubility increase of 1412× (~591.22 µg mL-1) for albendazole and 1373× (~144.66 µg mL-1) for fenbendazole. The dissolution rate of the drugs was significantly increased in binary and ternary systems, with hydroxypropyl-ß-cyclodextrin proving to be more effective. The presence of the water-soluble PVP-k30 increased the dissolution rate and amorphization of the complexes. Analysis of the changes in displacement and the profile of the cyclodextrin bands in the 1H NMR spectra revealed a molecular interaction and pointed to an effective complexation in the drug/cyclodextrin systems. Monomeric forms and nanoclusters of cyclodextrins were observed in the drug/cyclodextrin systems, suggesting that the increase in solubility of the drugs in the presence of cyclodextrins should not be attributed only to the formation of inclusion complexes, but also to the formation of cyclodextrin aggregates


Assuntos
Benzimidazóis/administração & dosagem , Ciclodextrinas/farmacocinética , Dissolução/classificação , Solubilidade , Preparações Farmacêuticas , Albendazol/análise , Fenbendazol/análise , Antiparasitários/análise
3.
J. bras. nefrol ; 39(2): 108-118, Apr.-June 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-893744

RESUMO

Abstract Introduction: It is still unknown how the pharmacological inhibition of the Renin Angiotensin System (RAS) impacts the levels of inflammation and fibrosis biomarkers. Objective: This study sought to evaluate the effect of enalapril, candesartan and aliskiren on urinary levels of cytokines in a model of chronic kidney disease (CKD). Methods: Male Wistar rats were submitted to surgical removal of ¾ of renal parenchyma to induce CKD (¾ nephrectomy), or subjected to sham surgery (control). Animals were then randomized into five groups: Sham surgery receiving vehicle; ¾ Nephrectomy receiving vehicle; ¾ Nephrectomy receiving enalapril (10 mg/kg); ¾ Nephrectomy receiving candesartan (10 mg/kg) and ¾ Nephrectomy receiving aliskiren (10 mg/kg). Urine output, water intake, mean arterial pressure (MAP) and urinary concentrations of creatinine, urea, albuminuria, Na+, K+, interleukin (IL) -1β, IL-6, IL-10 and transforming growth factor beta (TGF-β) were measured. Results: Nephrectomy significantly impaired renal function, increased MAP and altered the levels of all evaluated cytokines in urine. Enalapril, candesartan and aliskiren improved renal function and decreased MAP and IL-6 when compared to vehicle-treated nephrectomized group. Candesartan and aliskiren decreased IL-1β, while only candesartan reduced TGF-β and only aliskiren increased IL-10. Conclusion: Enalapril, candesartan and aliskiren presented similar effects on improving renal function and reducing MAP and urinary levels of IL-6 in rats with CKD. On the other hand, cytokine profile differed according to the treatment, suggesting that differential mechanisms were triggered in response to the site of RAS blockade.


Resumo Introdução: Ainda não se sabe como a inibição farmacológica do Sistema Renina Angiotensina (SRA) afeta os níveis de biomarcadores de inflamação e fibrose. Objetivo: Este estudo pretendeu avaliar o efeito de enalapril, candesartan e alisquireno sobre os níveis urinários de citocinas em um modelo de doença renal crônica (DRC). Métodos: Ratos Wistar machos foram submetidos à remoção cirúrgica de ¾ do parênquima renal para induzir DRC (nefrectomia), ou submetidos à cirurgia fictícia (controle). Animais foram então randomizados em cinco grupos: Cirurgia fictícia recebendo veículo; Nefrectomia recebendo veículo; Nefrectomia recebendo enalapril (10 mg/kg); Nefrectomia recebendo candesartan (10 mg/kg) e Nefrectomia recebendo alisquireno (10 mg/kg). Débito urinário, ingesta hídrica, pressão arterial media (PAM) e concentrações urinárias de creatinina, ureia, albumina, Na+, K+, interleucina (IL) -1β, IL-6, IL-10 e fator de transformação e crescimento beta (TGF-β) foram medidas. Resultados: A nefrectomia comprometeu significativamente a função renal, aumentou a PAM e alterou os níveis de todas as citocinas avaliadas na urina. Enalapril, candesartan e alisquireno melhoraram a função renal e diminuíram a PAM e a IL-6 quando comparado aos grupo de animais nefrectomizados tratados com veículo. Candesartan e alisquireno reduziram IL-1β, enquanto somente candesartan diminuiu o TGF-β e somente alisquireno aumentou a IL-10. Conclusão: Enalapril, candesartan e alisquireno apresentaram efeitos similares em relação à melhora da função renal e redução da PAM e dos níveis urinários de IL-6 em ratos com DRC. Por outro lado, o perfil de citocinas diferiu de acordo com o tratamento, sugerindo que diferentes mecanismos sejam desencadeados em resposta ao local de bloqueio do SRA.


Assuntos
Animais , Masculino , Ratos , Benzimidazóis/farmacologia , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Enalapril/farmacologia , Citocinas/urina , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Amidas/farmacologia , Sistema Renina-Angiotensina/efeitos dos fármacos , Tetrazóis/farmacologia , Distribuição Aleatória , Ratos Wistar , Fumaratos/farmacologia , Nefrectomia
4.
Braz. j. med. biol. res ; 50(11): e6665, 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-888944

RESUMO

Minimal hepatic encephalopathy is more common than the acute syndrome. Losartan, the first angiotensin-II receptor blocker (ARB), and candesartan, another widely-used ARB, have protected against developing fibrogenesis, but there is no clear data about their curative antifibrotic effects. The current study was designed to examine their effects in an already-established model of hepatic fibrosis and also their effects on the associated motor dysfunction. Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg−1·day−1) intraperitoneally for 2 weeks. The TAA-CLF rats were randomly divided into five groups (n=8) treated orally for 14 days (mg·kg−1·day−1) as follows: TAA (distilled water), losartan (5 and 10 mg/kg), and candesartan (0.1 and 0.3 mg/kg). Rats were tested for rotarod and open-field tests. Serum and hepatic biochemical markers, and hepatic histopathological changes were evaluated by H&E and Masson's staining. The TAA-CLF rats showed significant increases of hepatic malondialdehyde, hepatic expression of tumor necrosis factor-α (TNF-α), and serum ammonia, alanine aminotransferase, γ-glutamyl transferase, TNF-α, and malondialdehyde levels as well as significant decreases of hepatic and serum glutathione levels. All treatments significantly reversed these changes. The histopathological changes were moderate in losartan-5 and candesartan-0.1 groups and mild in losartan-10 and candesartan-0.3 groups. Only candesartan significantly improved TAA-induced motor dysfunction. In conclusion, therapeutic antifibrotic effects of losartan and candesartan in thioacetamide-induced hepatic fibrosis in rats are possibly through angiotensin-II receptor blocking, antioxidant, and anti-inflammatory activities. Improved motor dysfunction by candesartan could be attributed to better brain penetration and slower "off-rate" from angiotensin-II receptors. Clinical trials are recommended.


Assuntos
Animais , Masculino , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Benzimidazóis/uso terapêutico , Doença Hepática Terminal/complicações , Losartan/uso terapêutico , Transtornos Motores/tratamento farmacológico , Tetrazóis/uso terapêutico , Alanina Transaminase/sangue , Amônia/sangue , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Benzimidazóis/farmacologia , Modelos Animais de Doenças , Doença Hepática Terminal/patologia , Doença Hepática Terminal/fisiopatologia , Ensaio de Imunoadsorção Enzimática , gama-Glutamiltransferase/sangue , Glutationa/análise , Cirrose Hepática/complicações , Cirrose Hepática/patologia , Cirrose Hepática/fisiopatologia , Fígado/efeitos dos fármacos , Fígado/patologia , Locomoção/fisiologia , Losartan/farmacologia , Malondialdeído/análise , Transtornos Motores/etiologia , Transtornos Motores/fisiopatologia , Distribuição Aleatória , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Tetrazóis/farmacologia , Tioacetamida , Resultado do Tratamento , Fator de Necrose Tumoral alfa/sangue
6.
Rev. Soc. Bras. Med. Trop ; 48(4): 445-453, July-Aug. 2015. tab, ilus
Artigo em Inglês | LILACS | ID: lil-755959

RESUMO

Abstract:INTRODUCTION:

The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica , involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the efficacy and tolerability of 2 schemes of TCBZ.

METHODS

: Eighty-four Peruvian children with F. hepatica eggs in their stools were allocated into 2 groups: 44 received 2 dosages of 7.5mg/kg each with a 12-h interval (Group I), and 40 received a single 10-mg/kg dose (Group II). Evaluation of efficacy was based on the presence of eggs in stools, and tolerability was based on the presence of symptoms and signs post-treatment.

RESULTS

: A parasitological cure was obtained in 100% of individuals from Group I and 95% of individuals from Group II. The most common adverse event was biliary colic.

CONCLUSIONS

: The tested scheme was efficacious and tolerable, and it might be an optimal scheme in the region. To the best of our knowledge, this represents the largest series of children treated with TCBZ in a non-hospital setting.

.


Assuntos
Adolescente , Animais , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Anti-Helmínticos/administração & dosagem , Benzimidazóis/administração & dosagem , Fasciolíase/tratamento farmacológico , Anti-Helmínticos/efeitos adversos , Benzimidazóis/efeitos adversos , Protocolos Clínicos , Esquema de Medicação , Fasciola hepatica , Fezes/parasitologia , Contagem de Ovos de Parasitas , Peru , Índice de Gravidade de Doença
7.
Rev. bras. ginecol. obstet ; 37(1): 36-41, 01/2015. tab
Artigo em Português | LILACS | ID: lil-732874

RESUMO

OBJETIVO: Avaliar a preservação da fertilidade e dos ovários em mulheres submetidas à cirurgia por tumor anexial benigno. MÉTODOS: Para este estudo observacional com coleta prospectiva foram incluídas 206 mulheres operadas no CAISM-Unicamp de fevereiro de 2010 a janeiro de 2014. A preservação da fertilidade foi definida como tumorectomia ou anexectomia unilateral sem histerectomia em mulheres na pré-menopausa. A preservação ovariana foi considerada quando pelo menos um ovário ou parte dele foi preservado. RESULTADOS: Das 206 mulheres com tumores anexiais benignos, 120 (58%) estavam na pré-menopausa e 86 (42%) na pós-menopausa. Na pré-menopausa, foram encontrados 36 (30%) tumores de células germinativas, 31 (26%) neoplasias epiteliais e 11 (9%) do cordão sexual e estroma. Na pós-menopausa foram identificados 35 (41%) neoplasias epiteliais, 27 (31%) do cordão sexual e estroma e 8 (9%) de células germinativas. Entre as 36 mulheres com tumores ovarianos não neoplásicos, 21 (58%) apresentavam endometriomas e 8 (22%) cistos funcionais. Das 22 mulheres com tumores extra ovarianos, o leiomioma uterino foi o achado mais frequente (50%). Entre as pacientes com ≤35 anos, 26 (57%) foram submetidas à tumorectomia e 18 (39%) a anexectomia unilateral com preservação do útero e anexo contralateral. Mulheres com ≤35 anos foram mais frequentemente operadas por laparoscopia que esteve associada a maior taxa de preservação de fertilidade quando comparada com a laparotomia (p<0,01). Observou-se que 26 das pacientes submetidas à histerectomia com anexectomia (28%) bilateral estavam na pré-menopausa. CONCLUSÕES: Embora se observe uma tendência em realizar apenas tumorectomia em mulheres com ≤35 anos, uma proporção significativa de mulheres jovens ainda é ...


PURPOSE: To evaluate the sparing of fertility and ovaries in women submitted to surgical treatment for benign adnexal tumors. METHODS: Between February 2010 and January 2014, 206 patients were included in this observational study as they were submitted to surgical treatment for benign ovarian tumors at CAISM, a tertiary hospital. Fertility sparing surgery was defined as tumorectomy or unilateral salpingoophorectomy without hysterectomy in premenopausal women. Preservation of the ovary occurred when at least one ovary or part of it was mantained. RESULTS: Of the 206 women with benign tumors, 120 (58%) were premenopausal and 86 (42%) were postmenopausal. There were 36 (30%) ovarian germ cell tumors, 31 (26%) epithelial neoplasms and 11 (9%) sex-cord stromal tumors among premenopausal women. In the group of postmenopausal women, 35 (41%) epithelial neoplasms, 27 (31%) sex-cord stromal tumors and 8 (9%) ovarian germ cell tumors were identified. Among 36 women with non-neoplastic ovarian tumors, 21 (58%) had endometriomas and 8 (22%) functional cysts. Among 22 women with extra-ovarian tumors, uterine leiomyomatosis was the most frequent finding (50%). In the group of women who were ≤35 years old, 26 (57%) were treated by tumorectomy and 18 (39%) were submitted to unilateral salpingoophorectomy with sparing of the uterus and the contralateral ovary. Women who were ≤35 years old were more frequently operated by laparoscopy which was associated with a higher number of fertility sparing procedures when compared to laparotomy (p<0.01). Twenty-six (28%) women submitted to hysterectomy with bilateral salpingoophorectomy were premenopausal. CONCLUSION: Although there is a trend to perform only tumorectomy in women who are ≤35 years old, a significant number of young women is still treated by salpingoophorectomy. Among 36- to 45-year-old women, only 70% had their fertility spared, while 20% had both ovaries removed. ...


Assuntos
Animais , Masculino , Camundongos , Ratos , Células da Medula Óssea , Eritrócitos/efeitos dos fármacos , Citometria de Fluxo/métodos , Testes para Micronúcleos , Benzimidazóis , Separação Celular , Envelhecimento Eritrocítico , Compostos de Epóxi/toxicidade , Eritrócitos/citologia , Corantes Fluorescentes , Glicóis/toxicidade , Mutagênicos/toxicidade , Ratos Sprague-Dawley
8.
Rev. panam. salud pública ; 36(5): 331-335, nov. 2014.
Artigo em Espanhol | LILACS | ID: lil-733236

RESUMO

Desde diciembre de 2013, la Región de las Américas se enfrenta por primera vez a una epidemia de chikungunya. Los casos iniciales se registraron en el Caribe francés y, debido al comercio y la movilización de personas, esta epidemia no tardó en llegar a la República Dominicana, cuya población es de 10 millones de habitantes y comparte con Haití la isla La Española. En este artículo se difunde información extraída de diversos artículos y documentos oficiales sobre el virus, la infección y la epidemia de chikungunya, que han sido de gran ayuda para orientar la respuesta en la República Dominicana y pueden ser útiles para mejorar tanto el conocimiento como las actuaciones frente a la epidemia de los trabajadores del sector salud de la Región. Se destaca la importancia que revisten las investigaciones realizadas en países y territorios afectados del océano Índico, como la isla de Reunión, durante la epidemia declarada entre 2005 y 2007, cuando se registró una tasa de ataque mayor de 30%, se identificaron los grupos de riesgo, las formas graves y atípicas de la infección, la transmisión vertical del virus, las formas crónicas, que pueden provocar dolores recurrentes durante tres años, y las defunciones directa o indirectamente relacionadas con el virus chikungunya. Por su alta tasa de ataque, el virus chikungunya se convierte en un reto sin precedentes para los ministerios de salud, que exige una adecuada organización de los servicios de salud, la priorización de la atención a los grupos de riesgo y a los pacientes con formas graves de la enfermedad, así como una adecuada comunicación social y respuesta intersectorial.


The Region of the Americas has been affected since December 2013 by a chikungunya epidemic for the first time. Although the first cases were recorded in the French Caribbean, the epidemic quickly spread to the Dominican Republic due to trade and people movements. The Dominican Republic, which shares the island of Hispaniola with Haiti, has a population of 10 million. This article contains information from a range of different publications and official documents about the chikungunya virus infection and epidemic. These papers were extremely helpful for guiding the response to the epidemic in the Dominican Republic and may also be useful for enhancing knowledge of the virus and responses among health workers elsewhere in the region. Particular attention is drawn to the important research undertaken in countries and territories affected by the epidemic in the Indian Ocean area. This is the case, for example, of the island of La Réunion, where the epidemic had an attack rate of more than 30% between 2005 and 2007. Researchers were able to identify risk groups, severe and atypical forms of the infection, cases of vertical transmission, chronic disease causing recurrent pain over three years, and directly- or indirectly-related deaths from the virus. Given its high attack rate, the chikungunya virus has emerged as an exceptional challenge for health ministries and calls for appropriate organized responses from the health services, prioritization of care for risk groups and patients exhibiting severe forms of the disease, and effective social communication and intersectoral actions.


Assuntos
Animais , Ratos , Angiotensina II/farmacologia , DNA , Músculo Liso Vascular/efeitos dos fármacos , Inibidores da Agregação de Plaquetas/farmacologia , /análogos & derivados , Vasoconstritores/farmacologia , Anti-Hipertensivos/farmacologia , Benzimidazóis/farmacologia , Compostos de Bifenilo/farmacologia , Células Cultivadas , Divisão Celular/fisiologia , Músculo Liso Vascular/fisiologia , Proteínas Proto-Oncogênicas c-fos/biossíntese , Ratos Endogâmicos WKY , RNA Mensageiro/metabolismo , Tetrazóis/farmacologia , /farmacologia
9.
Rev. méd. Chile ; 142(10): 1330-1333, oct. 2014. ilus
Artigo em Espanhol | LILACS | ID: lil-731665

RESUMO

Human fascioliasis is a parasitic zoonosis that affects the liver of human and herbivorous animals. In chronic cases, its diagnosis is confirmed by direct visualization of parasitic eggs in stool examination, by positive testing for Fasciola hepatica antigens in stools, or by direct observation of parasites by endoscopic retrograde cholangiography or surgery. In acute cases, serological reactions as immunoblothing or detection of parasite antigens in the blood are useful. The treatment of choice is triclabendazole. However, parasite resistance in animals, as well as in man, has been reported to this drug. We report four patients in whom the parasitic infection persisted despite a course of treatment with triclabendazole.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Anti-Helmínticos/administração & dosagem , Benzimidazóis/administração & dosagem , Resistência a Medicamentos , Fasciolíase/tratamento farmacológico , Fasciolíase/diagnóstico
10.
Mem. Inst. Oswaldo Cruz ; 109(6): 757-760, 09/09/2014. graf
Artigo em Inglês | LILACS | ID: lil-724000

RESUMO

Trypanosoma cruzi has a particular cytoskeleton that consists of a subpellicular network of microtubules and actin microfilaments. Therefore, it is an excellent target for the development of new anti-parasitic drugs. Benzimidazole 2-carbamates, a class of well-known broad-spectrum anthelmintics, have been shown to inhibit the in vitro growth of many protozoa. Therefore, to find efficient anti-trypanosomal (trypanocidal) drugs, our group has designed and synthesised several benzimidazole derivatives. One, named JVG9 (5-chloro-1H-benzimidazole-2-thiol), has been found to be effective against T. cruzi bloodstream trypomastigotes under both in vitro and in vivo conditions. Here, we present the in vitro effects observed by laser scanning confocal and scanning electron microscopy on T. cruzi trypomastigotes. Changes in the surface and the distribution of the cytoskeletal proteins are consistent with the hypothesis that the trypanocidal activity of JVG9 involves the cytoskeleton as a target.


Assuntos
Benzimidazóis/farmacologia , Citoesqueleto/efeitos dos fármacos , Estágios do Ciclo de Vida/efeitos dos fármacos , Tripanossomicidas/farmacologia , Trypanosoma cruzi/efeitos dos fármacos , Actinas/isolamento & purificação , Flagelos/efeitos dos fármacos , Microscopia Eletrônica de Varredura , Microscopia de Fluorescência , Trypanosoma cruzi/crescimento & desenvolvimento , Trypanosoma cruzi/ultraestrutura , Tubulina (Proteína)/isolamento & purificação
11.
Rev. méd. Chile ; 142(7): 880-888, jul. 2014. tab
Artigo em Espanhol | LILACS | ID: lil-726179

RESUMO

Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.


Assuntos
Humanos , Anticolesterolemiantes/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Anticorpos Monoclonais/uso terapêutico , Benzimidazóis/uso terapêutico , Ensaios Clínicos como Assunto , Oligonucleotídeos/uso terapêutico , Pró-Proteína Convertases/uso terapêutico , Serina Endopeptidases/uso terapêutico
12.
Medicina (B.Aires) ; 74(2): 121-123, abr. 2014. tab
Artigo em Espanhol | LILACS | ID: lil-708592

RESUMO

El dabigatrán es un nuevo inhibidor directo de la trombina, de administración oral, empleado para la prevención de eventos tromboembólicos en pacientes con fibrilación auricular no valvular. A diferencia de la warfarina, no se dispone de un antídoto conocido. La hemodiálisis ha sido sugerida como un método para remover el dabigatrán y reducir el efecto anticoagulante. Se presenta el caso de un paciente con antecedente de fibrilación auricular y medicado con dabigatrán, que fue admitido en el hospital para una cirugía abdominal de urgencia. A las seis horas de la última dosis recibida, los estudios de coagulación mostraban alteración. Ante la falta de antídoto para revertir los efectos, se decidió realizar hemodiálisis. Luego de tres horas de diálisis los parámetros de coagulación tendieron a normalizarse y el paciente fue operado sin presentar hemorragias anormales durante la cirugía o en el postoperatorio.


Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation. Unlike warfarin, dabigatran has no known antidote. Hemodialysis has been suggested as a method for removing dabigatran and thereby reducing its anticoagulant effect. We report the case of a patient with a known history of atrial fibrillation, treated with dabigatran, who was admitted for emergency abdominal surgery. At six hours after the last dose received, coagulation studies were altered. In absence of an antidote to reverse its effects, it was decided to perform hemodialysis. After three hours of dialysis coagulation parameters were improved and the patient underwent surgery without showing abnormal bleeding during surgery or in the postoperative period.


Assuntos
Idoso de 80 Anos ou mais , Humanos , Masculino , Antitrombinas/sangue , Benzimidazóis/sangue , Diverticulite/cirurgia , Emergências , Diálise Renal , beta-Alanina/análogos & derivados , Antitrombinas/uso terapêutico , Fibrilação Atrial/sangue , Fibrilação Atrial/tratamento farmacológico , Testes de Coagulação Sanguínea , Benzimidazóis/uso terapêutico , Dabigatrana , Diverticulite/sangue , beta-Alanina/sangue , beta-Alanina/uso terapêutico
13.
Clinics ; 69(2): 145-149, 2/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-701377

RESUMO

OBJECTIVE: To evaluate the effect of blocking the angiotensin II AT-1 receptor by the systemic administration of candesartan on the expression of intercellular adhesion molecule-1 in the sclera and choroid of hypercholesterolemic rabbits. METHODS: New Zealand rabbits were divided into 3 groups, as follows: GI, which was fed a rabbit standard diet; GII, which was fed a hypercholesterolemic diet; and GIII, which received hypercholesterolemic diet plus candesartan. Samples of the rabbits' sclera and choroid were then studied by hematoxylin-eosin staining and histomorphometric and immunohistochemical analyses for intercellular adhesion molecule-1 expression. RESULTS: Histological analysis of hematoxylin- and eosin-stained sclera and choroid revealed that macrophages were rarely present in GI, and GII had significantly increased macrophage numbers compared to GIII. Moreover, in GII, the sclera and choroid morphometry showed a significant increase in thickness in comparison to GI and GIII. GIII presented a significant increase in thickness in relation to GI. Sclera and choroid immunohistochemical analysis for intercellular adhesion molecule-1 expression revealed a significant increase in immunoreactivity in GII in relation to GI and GIII. GIII showed a significant increase in immunoreactivity in relation to GI. CONCLUSION: Candesartan reduced the expression of intercellular adhesion molecule-1 and consequently macrophage accumulation in the sclera and choroid of hypercholesterolemic rabbits. .


Assuntos
Animais , Masculino , Coelhos , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Benzimidazóis/farmacologia , Corioide/efeitos dos fármacos , Hipercolesterolemia/fisiopatologia , Molécula 1 de Adesão Intercelular/efeitos dos fármacos , Esclera/efeitos dos fármacos , Tetrazóis/farmacologia , Corioide/anatomia & histologia , Modelos Animais de Doenças , Imuno-Histoquímica , Macrófagos/efeitos dos fármacos , Degeneração Macular/fisiopatologia , Valores de Referência , Esclera/anatomia & histologia
14.
Rio de Janeiro; s.n; 2014. xiii,120 p. ilus, graf, tab, mapas.
Tese em Português | LILACS | ID: lil-772801

RESUMO

Os tratamentos disponíveis para a doença de Chagas e as leishmanioses não são eficientes e apresentam alta toxicidade. Diversos estudos mostram que há possibilidade de indução de resistência de Trypanosoma cruzi ao Benznidazol (BZ) o que pode interferir na eficácia do tratamento. O mesmo tem sido relatado com relação aos fármacos utilizados para o tratamento das leishmanioses, embora não exista um mecanismo de ação definido para a resistência a drogas nestes protozoários. Neste trabalho foram focalizados dois potenciais mecanismos: 1) atividade da glicoproteína-P (Pgp), uma proteína de membrana que atua como uma bomba de efluxo dependente de energia e associada ao fenótipo de resistência a múltiplas drogas (MDR); 2) a enzima nitrorredutase presente em T. cruzi (TcNTR), reponsável pela redução de nitroderivados, como BZ, para obter o efeito tripanocida. Na busca de novos compostos seletivos contra T. cruzi e Leishmania amazonensis, nosso grupo vem estudando derivados da classe das tiossemicarbazonas. Em estudos prévios foi observado que o derivado 4-N-(2-metoxi-estiril)-tiossemicarbazona (2-MEOTIO) foi o composto mais efetivo sobre diferentes formas de T. cruzi, enquanto 4-N-(4’-hidroxi-3’-metoxi-estiril)-tiossemicarbazona (3-MEOTIO) se mostrou o mais eficiente contra L. amazonensisO mecanismo de resistência a estes compostos foi avaliado, e nossos resultados mostram a participação da Pgp na resistência a 2-MEOTIO e BZ em T. cruzi, e a 3-MEOTIO em L. amazonensis...


The available drugs for the treatment of Chagas disease and leishmaniasisare not efficient and cause toxic side effects. Several studies show the possibilityof drug resistance induction to Benznidazol (BZ) in Trypanosoma cruzi, whichmay interfere with the treatment efficacy. The same has been observed regardingcompounds used to treat leishmaniasis, although more studies on drug resistancemechanism are needed. In the present study we focused on two potential drugresistance mechanisms: 1) P-glycoprotein (Pgp) activity, a membrane proteinwhich acts as an efflux pump energy-dependent and is associated with themultidrug resistance fenotype (MDR); 2) the enzyme nitroreductase (TcNTR)found in T. cruzi, which is responsible for the reduction of nitroheterocyclicderivatives, such as Bz and Nifurtimox, generating metabolites with trypanocidalactivity. In the search for new selective drugs for the treatment of Chagas diseaseand leishmaniasis, our group has been studying compounds from the class of thethiosemicarbazones. Previous studies showed that the 4-N-(2-methoxy-styryl)-thiosemicarbazone (2-MEOTIO) was the most efficient compound on differentforms of T. cruzi, whereas 4-N-(4’-hidroxy-3’-methoxy styryl)-thiosemicarbazone(3-MEOTIO) was the most active on Leishmania amazonensis. Here weevaluated the drug resistance mechanism to both thiosemicarbazone derivatives,as well as, to BZ which was used as reference drug for T. cruzi. Our results showthe participation of Pgp in the resistance to both 2-MEOTIO and BZ in T. cruzi, aswell as in the resistance in L. amazonensis to the compound 3-MEOTIO.Interestingly, in T. cruzi the participation of Pgp is related to its localization notonly in the plasma membrane but also in the mithocondrion...


Assuntos
Humanos , Benzimidazóis/uso terapêutico , Doença de Chagas , Resistência a Medicamentos , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/uso terapêutico , Leishmaniose , Doenças Negligenciadas , Nifurtimox
15.
Rev. bras. parasitol. vet ; 22(4): 548-553, Oct-Dec/2013. tab, graf
Artigo em Inglês | LILACS | ID: lil-698003

RESUMO

Anthelmintic resistance is an increasing problem that threatens livestock production worldwide. Understanding of the genetic basis of benzimidazole resistance recently allowed the development of promising molecular diagnostic tools. In this study, isolates of Haemonchus contortus obtained from goats, sheep and buffaloes raised in Brazil were screened for presence of the polymorphism Phe200Tyr in the β-tubulin 1 gene, which confers resistance to benzimidazole. The allelic frequency of the mutation conferring resistance ranged from 7% to 43%, and indicated that resistance to benzimidazole could be found in nematodes isolated from all the ruminant species surveyed. Although significant variation in the frequency of the F200Y mutation was observed between different herds or host species, no significant variation could be found in populations isolated from animals within the same herd. These findings suggest that screening of samples from a few animals has the potential to provide information about the benzimidazole resistance status of the entire herd, which would enable a considerable reduction in the costs of diagnosis for the producer. Molecular diagnosis has practical advantages, since it can guide the choice of anthelmintic drug that will be used, before its application in the herd, thus reducing the economic losses driven by anthelmintic resistance.


A resistência aos anti-helmínticos é um problema crescente que ameaça a produção pecuária em todo o mundo. A compreensão da base genética da resistência ao benzimidazol permitiu, recentemente, o desenvolvimento de métodos diagnósticos moleculares promissores. Neste estudo, isolados de Haemonchus contortus obtidos a partir de rebanhos de caprinos, ovinos e bubalinos criados no Brasil foram avaliados quanto à presença do polimorfismo F200Y no gene da β-tubulina1, o qual confere resistência ao benzimidazol. A frequência alélica da mutação variou de 7% a 43%, indicando que a resistência ao benzimidazol pode ser encontrada em nematoides isolados a partir de todas as espécies de ruminantes pesquisadas. Embora tenha sido observada variação significativa das frequências de mutação F200Y entre rebanhos/espécies hospedeiros distintos, não foi encontrada variação significativa entre populações isoladas de animais dentro de um mesmo rebanho. Estes achados sugerem que a avaliação de amostras de alguns poucos animais tem o potencial de fornecer informações sobre o nível de resistência ao benzimidazol de todo o rebanho, possibilitando uma redução considerável dos custos de diagnóstico para o produtor. O diagnóstico molecular apresenta vantagens práticas, uma vez que pode guiar a escolha da base anti-helmíntica a ser utilizada antes da sua aplicação no rebanho, reduzindo, portanto, as perdas ocasionadas pela resistência aos fármacos anti-helmínticos.


Assuntos
Animais , Feminino , Masculino , Anti-Helmínticos/farmacologia , Anti-Helmínticos/uso terapêutico , Benzimidazóis/farmacologia , Benzimidazóis/uso terapêutico , Búfalos/parasitologia , Doenças das Cabras/tratamento farmacológico , Cabras/parasitologia , Hemoncose/veterinária , Haemonchus/efeitos dos fármacos , Doenças dos Ovinos/tratamento farmacológico , Ovinos/parasitologia , Resistência a Medicamentos/genética , Doenças das Cabras/parasitologia , Hemoncose/tratamento farmacológico , Hemoncose/parasitologia , Haemonchus/genética , Mutação , Doenças dos Ovinos/parasitologia
16.
Gastroenterol. latinoam ; 23(4): 201-205, oct.-dic. 2012. ilus
Artigo em Espanhol | LILACS | ID: lil-680414

RESUMO

Hepatic fascioliasis is produced by a platyhelminth, trematode: the hepatic Fasciola. In recent years, its incidence has increased in all countries, including Latin America. The diagnosis is based on clinical and epidemiological background information, hemogramm with eosinophil count; Ig G ELISA; and copro-parasitological and duodenal aspirate in search of parasite eggs. Images are useful, endoscopic ultrasound, Computed Tomography (CT), abdominal Magnetic Resonance Imaging (MRI), especially in case of complications. The endoscopic retrograde cholangiopancreatography (ERCP) is useful both for diagnosis and treatment (extraction of adult Fasciola), as it was in hte present clinical case. This parasite can also be found incidentally in the course of a surgery planned for other reasons. In the present clinical case we present a 41-year-old patient, farmer, with apparent ingestion of water and contaminated aquatic vegetables. Initially he presented only fever and hypereosinophilia; with fascioliasis diagnosis. The pathology recurred after 18 month with biliary obstruction. The clinical and epidemiological background information was a fundamental tool for diagnosis, together with abdominal CT. Initially it evolved with bad response to several antiparasitic treatments and then it progressed positively. After that, the pathology recurred with complications. ERCP was performed to extract adult Fasciola. Currently in symptomatic remission after endoscopic intervention and drug treatment.


La fascioliasis hepática es producida por un platelminto, tremátodo: la Fasciola hepática. En los últimos años ha incrementado su incidencia en todos los países, incluyendo América Latina. El diagnóstico se basa en los antecedentes clínicos, epidemiológicos, hemograma con recuento de eosinófilos; IgG Elisa; copro-parasitológicos y aspirado duodenal en búsqueda de huevo de parásitos. Las imágenes son de utilidad, endosonografía, tomografía computada (TC), resonancia magnética (RM) abdominal, especialmente en caso de complicaciones. La colangio-pancreatografía retrógrada endoscópica (CPRE) es útil tanto como para el diagnóstico como para el tratamiento (extracción de fasciolas adultas), como se realizó en el presente caso clínico. Este parásito también se puede encontrar incidentalmente en el transcurso de una cirugía por otros motivos. Presentamos el caso de un paciente de 41 años, originario de una zona rural, agricultor, con ingesta aparente de agua y vegetales acuáticos contaminados. Cursó inicialmente sólo con fiebre e hipereosinofilia; con diagnóstico de fascioliasis. Al cabo de 18 meses su patología recurrió con cuadro clínico de obstrucción biliar. El antecedente clínico y epidemiológico fue una herramienta fundamental para el diagnóstico, además, de la TC abdominal. Evolucionó inicialmente con mala respuesta a varios tratamientos antiparasitarios, y luego mejoró. Posteriormente, su patología recurrió con complicaciones. Se realizó CPRE con extracción de Fasciolas adultas. Actualmente, se encuentra en remisión sintomática mantenida, después de la intervención endoscópica y el tratamiento medicamentoso.


Assuntos
Humanos , Masculino , Adulto , Fasciola hepatica , Fasciolíase/diagnóstico , Fasciolíase/terapia , Anti-Helmínticos/uso terapêutico , Benzimidazóis/uso terapêutico , Colangiopancreatografia Retrógrada Endoscópica
17.
Rev. chil. neuro-psiquiatr ; 50(4): 239-248, dic. 2012. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-671280

RESUMO

Introduction: Atrial fibrillation (AF) is the most common arrhythmia. AF increases stroke risk by 5-fold and accounts for 15 percent of stroke. For more than 50 years, vitamin K antagonists were the only available oral anticoagulation. The two major classes of novel oral agents are direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (apixaban or rivaroxaban). These new agents require no routine laboratory monitoring and they are administered in a fixed dose. Method: A non systematic literature review was performed. Results: We performed a critical review of articles about new oral anticoagulants in stroke prevention. We evaluated properties of these agents and we compare efficacy and safety outcomes shown in clinical trials about new oral anticoagulants in AF. Discussion: New oral anticoagulants are at least as good as warfarin at preventing stroke in patients with AF. They seem to be safer than warfarin with significantly less intracranial bleeding. Trials demonstrate dabigatran to be the most effective in decreasing ischemic strokes, apixaban superior to warfarin with statistically lower mortality, and rivaroxaban no worse than warfarin for those with higher stroke risk. Conclussion: New oral anticoagulants have several advantages in comparison with warfarin, but we need further trials to know better the efficacy and safety of these new agents.


Introducción: La fibrilación auricular (FA) es la arritmia más frecuente, se asocia a un riesgo 5 veces mayor de ataque cerebrovascular (ACV), y da cuenta del 15 por ciento de los ACV isquémicos. Por más de medio siglo el tratamiento anticoagulante oral en FA ha estado limitado al uso de antagonistas de la vitamina K. Los nuevos anticoagulantes orales, se clasifican en dos categorías principales: inhibidores de la trombina como el dabigatrán y los inhibidores del factor Xa, como el apixabán y el rivaroxabán. Estos fármacos no requieren monitorización de los niveles de anticoagulación y se administran en dosis fija. Método: Revisión no sistemática de la literatura. Resultados: Se analizan de manera crítica los artículos sobre nuevos anticoagulantes orales en la prevención de ACV. Se evalúan las propiedades de estos nuevos agentes y se comparan los desenlaces de eficacia y de seguridad de los ensayos clínicos de los estos fármacos. Discusión: Los nuevos anticoagulantes orales son al menos tan efectivos que la warfarina en la prevención de ACV cardioembólico en pacientes con FA. Parecen ser más seguros con menor frecuencia de hemorragia intracranial. El dabigatrán es el más efectivo en disminuir el ACV isquémico, el apixabán es superior a la warfarina con una mortalidad significativamente inferior, y el rivaroxabán es no inferior a warfarina para pacientes con alto riesgo de ACV. Conclusión: Los nuevos anticoagulantes orales ofrecen varias ventajas en comparación a warfarina, sin embargo, se requiere se estudios adicionales para conocer más detalladamente su efectividad y perfil de seguridad.


Assuntos
Humanos , Acidente Vascular Cerebral/prevenção & controle , Anticoagulantes/administração & dosagem , Fibrilação Atrial/tratamento farmacológico , Administração Oral , Benzimidazóis/administração & dosagem , Morfolinas/administração & dosagem , Pirazóis/administração & dosagem , Varfarina/administração & dosagem , beta-Alanina/análogos & derivados
18.
Rev. méd. Chile ; 140(8): 1073-1077, ago. 2012. ilus
Artigo em Espanhol | LILACS | ID: lil-660061

RESUMO

Background & Aims: Rebound acid hypersecretion (RAHS) has been demonstrated after 8 weeks of treatment with a proton-pump inhibitor (PPI). IfRAHS induces acid-related symptoms, this might lead to PPI dependency and thus have important implications. Methods: A randomized, double-blind, placebo-controlled trial with 120 healthy volunteers was conducted. Participants were randomized to 12 weeks of placebo or 8 weeks of esomeprazole 40 mg/d followed by 4 weeks with placebo. The Gastrointestinal Symptom Rating Scale (GSRS) was filled out weekly. A score of >2 on 1 of the questions regarding heartburn, acid regurgitation, or dyspepsia was defined as a clinically relevant acid-related symptom. Results: There were no significant differences between groups in GSRS scores at baseline. GSRS scores for acid-related symptoms were significantly higher in the PPIgroup at week 10 (1.4 ± 1.4 vs 1.2 ± 0.9; P = .023), week 11 (1.4 ± 1.4 vs 1.2 ± 0.9; P = .009), and week 12 (1.3 ± 1.2 vs 1.0 ± 0.3; P = .001). Forty-four percent (26/59) of those randomized to PPI reported >1 relevant, acid-related symptom in weeks 9-12 compared with 15% (9/59; P < .001) in the placebo group. The proportion reporting dyspepsia, heartburn, or acid regurgitation in the PPIgroup was 13 of 59 (22%) at week 10,13 of59 (22%) at week 11, and 12 of 58 (21%) at week 12. Corresponding figures in the placebo group were 7% at week 10 (P = .034), 5% at week 11 (P = .013), and 2% at week 12 (P = .001). Conclusions: PPI therapy for 8 weeks induces acid-related symptoms in healthy volunteers after withdrawal. This study indicates unrecognized aspects of PPI withdrawal and supports the hypothesis that RAHS has clinical implications.


Assuntos
Humanos , Pessoa de Meia-Idade , Bloqueadores do Receptor Tipo 1 de Angiotensina II/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Benzimidazóis/efeitos adversos , Benzoatos/efeitos adversos , Doenças Cardiovasculares/tratamento farmacológico , Proteinúria/induzido quimicamente , Ramipril/efeitos adversos , Bloqueadores do Receptor Tipo 1 de Angiotensina II/administração & dosagem , Inibidores da Enzima Conversora de Angiotensina/administração & dosagem , Benzimidazóis/administração & dosagem , Benzoatos/administração & dosagem , Ensaios Clínicos como Assunto , Quimioterapia Combinada , Taxa de Filtração Glomerular/efeitos dos fármacos , Estudos Multicêntricos como Assunto , Ramipril/administração & dosagem
19.
Rev. cuba. med. trop ; 63(3): 268-274, sep.-dic. 2011.
Artigo em Espanhol | LILACS | ID: lil-615572

RESUMO

Introducción: la fasciolosis, por Fasciola hepatica, muestra a escala mundial un incremento en la incidencia de enfermos en los últimos años. Cuba se encuentra entre aquellos países donde se reportan casos esporádicos y algunos brotes epidémicos. Objetivo: describir el comportamiento clínico-terapéutico de esta trematodiosis de trasmisión digestiva en una serie de 87 pacientes ingresados en el Instituto de Medicina Tropical "Pedro Kourí" desde enero de 1996 a diciembre de 2005. Método: los pacientes se dividieron en 2 grupos atendiendo al fármaco prescrito, dihidroemetina o triclabendazol. Se recogieron las variables clínicas al inicio del diagnóstico y 90 d después del tratamiento; se hallaron las medias y la desviación estándar. Resultados: el sexo masculino predominó discretamente con 54 por ciento en nuestra serie de pacientes ingresados en el servicio de medicina tropical del instituto. La ingestión de berro (Nasturtium officinale) estuvo presente en casi la mitad de los pacientes. El dolor abdominal, fiebre y astenia resultaron los síntomas de mayor frecuencia. El triclabendazol y la dihidroemetina fueron útiles en el tratamiento. Conclusiones: se comprobó la utilidad de los exámenes de laboratorio en el diagnóstico y seguimiento de los enfermos. Los antiparasitarios dihidroemetina y triclabendazol resultaron efectivos a las dosis utilizadas con efectos adversos menores.


Introduction: in the last few years, the Incidence rate of fascioliosis caused by Fasciola hepatica has increased worldwide. Cuba is one of the countries that have reported sporadic cases and also some outbreaks of fasciolosis. Objective: to describe clinical and therapeutic features of this trematodiasis of digestive transmission found in 87 patients, who had been admitted to "Pedro Kourí" Institute of Tropical Medicine from January 1996 to December 2005. Methods: patients were divided into 2 groups according to the prescribed drug, that is, triclabendazole and dihydroemetine. The clinical variables were collected at the time of diagnosis and 90 days after treatment; the means and the standard deviation were estimated. Results: males was slightly predominant (54) in our series of patients admitted to the institute service. Consumption of watercress (Nasturtium officinale) was found in almost half of the patients. Abdominal pain, fever and malaise were the most frequent symptoms. Both drugs were useful to treat F. hepatica. Conclusions: this study showed the usefulness of lab tests for diagnosis and follow-up of patients after treatment. The anti-parasitic drugs dihydroemetine and triclabendazole proved to be effective at the prescribed doses in this research with minor adverse effects.


Assuntos
Adolescente , Adulto , Animais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Anti-Helmínticos/uso terapêutico , Benzimidazóis/uso terapêutico , Emetina/análogos & derivados , Fasciolíase/diagnóstico , Fasciolíase/tratamento farmacológico , Emetina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA